HRP20141110T1 - Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo - Google Patents

Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo Download PDF

Info

Publication number
HRP20141110T1
HRP20141110T1 HRP20141110AT HRP20141110T HRP20141110T1 HR P20141110 T1 HRP20141110 T1 HR P20141110T1 HR P20141110A T HRP20141110A T HR P20141110AT HR P20141110 T HRP20141110 T HR P20141110T HR P20141110 T1 HRP20141110 T1 HR P20141110T1
Authority
HR
Croatia
Prior art keywords
human
integrin
alpha9
humanized anti
variable region
Prior art date
Application number
HRP20141110AT
Other languages
English (en)
Inventor
Kenji Uehara
Hirofumi Higuchi
Toshihiro Nakashima
Daisuke Ishikawa
Nobuchika Yamamoto
Hirotada Fujita
Fumihiko Sakai
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of HRP20141110T1 publication Critical patent/HRP20141110T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (15)

1. Humanizirano anti-humani-alfa9-integrin-protutijelo, naznačeno time, da obuhvaća varijabilno područje jakog lanca i varijabilno područje slabog lanca odabrane od sljedećih: (a) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:11 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:17; (b) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:13 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:17; (c) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:15 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:9;
2. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje jakog lanca od protutijela je humani Igγ1.
3. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje slabog lanca od protutijela je humani Igκ.
4. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje jakog lanca od protutijela je humani Igγ1 a konstantno područje slabog lanca od protutijela je humani Igκ.
5. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:19 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:25.
6. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:21 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:25.
7. Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:23 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:27.
8. Polinukleotid, naznačen time, da sadrži sekvencu koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1, i sekvencu koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1.
9. Vektor ekspresije, naznačen time, da sadrži polinukleotid koji obuhvaća sekvencu koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1, i polinukleotid koji obuhvaća sekvencu koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1.
10. Stanica domaćina, naznačena time, da je odabrana iz skupine koju čine sljedeće (a) i (b): (a) stanica domaćina transformirana s vektorom ekspresije koji sadrži polinukleotid sa sekvencom koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1 kao i polinukleotid sa sekvencom koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1; i (b) stanica domaćina transformirana s vektorom ekspresije koji sadrži polinukleotid sa sekvencom koja kodira varijabilno područje jakog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1 i s vektorom ekspresije koji sadrži polinukleotid sa sekvencom koja kodira varijabilno područje slabog lanca od humaniziranog anti-humani-alfa9-integrin-protutijela prema zahtjevu 1.
11. Postupak proizvodnje humaniziranog anti-humani-alfa9-integrin-protutijela, naznačen time, da obuhvaća fazu kultiviranja stanice domaćina prema zahtjevu 10, kako bi se omogućila ekspresija humaniziranog anti-humani-alfa9-integrin-protutijela.
12. Humanizirano anti-humani-alfa9-integrin-protutijelo, naznačeno time, da se proizvodi pomoću postupka prema zahtjevu 11.
13. Farmaceutski pripravak za reumatoidni artritis, naznačen time, da obuhvaća humanizirano anti-humani-alfa9-integrin-protutijelo prema bilo kojem od zahtjeva 1 do 7 i 12.
14. Humanizirano anti-humani-alfa9-integrin-protutijelo prema bilo kojem od zahtjeva 1 do 7 i 12, naznačeno time, da se upotrebljava kao lijek.
15. Humanizirano anti-humani-alfa9-integrin-protutijelo prema bilo kojem od zahtjeva 1 do 7 i 12, naznačeno time, da se upotrebljava u postupku prevencije ili liječenja reumatoidnog artritisa.
HRP20141110AT 2008-01-11 2014-11-17 Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo HRP20141110T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008004975 2008-01-11
JP2008282496 2008-10-31
PCT/JP2009/050187 WO2009088064A1 (ja) 2008-01-11 2009-01-09 改良型ヒト化抗ヒトα9インテグリン抗体
EP09700904.7A EP2243829B1 (en) 2008-01-11 2009-01-09 IMPROVED HUMANIZED ANTI-HUMAN alpha9-INTEGRIN ANTIBODY

Publications (1)

Publication Number Publication Date
HRP20141110T1 true HRP20141110T1 (hr) 2015-01-16

Family

ID=40853174

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141110AT HRP20141110T1 (hr) 2008-01-11 2014-11-17 Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo

Country Status (21)

Country Link
US (2) US8603476B2 (hr)
EP (2) EP2243829B1 (hr)
JP (2) JPWO2009088065A1 (hr)
KR (1) KR101634636B1 (hr)
CN (1) CN101918549B (hr)
AU (1) AU2009203369B2 (hr)
BR (1) BRPI0905656B8 (hr)
CA (1) CA2711882C (hr)
CY (1) CY1115897T1 (hr)
DK (1) DK2243829T3 (hr)
ES (1) ES2519047T3 (hr)
HR (1) HRP20141110T1 (hr)
IL (1) IL206898A (hr)
MX (1) MX2010007515A (hr)
PL (1) PL2243829T3 (hr)
PT (1) PT2243829E (hr)
RU (1) RU2503720C2 (hr)
SI (1) SI2243829T1 (hr)
TW (1) TWI432453B (hr)
WO (2) WO2009088064A1 (hr)
ZA (1) ZA201004770B (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101667227B1 (ko) * 2009-03-10 2016-10-18 가부시키가이샤 진 테크노 사이언스 인간화된 k33n 단일 클론 항체의 제조, 발현 및 해석
WO2011004847A1 (ja) * 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 新規ヒト化抗ヒトα9インテグリン抗体
AU2012252152B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US20140294819A1 (en) * 2011-10-13 2014-10-02 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
JP2021008406A (ja) * 2017-09-29 2021-01-28 アステラス製薬株式会社 改良型ヒト化抗ヒトα9インテグリン抗体含有医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU681633B2 (en) 1993-03-11 1997-09-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
CN100469793C (zh) 2001-04-05 2009-03-18 株式会社免疫生物研究所 抗骨桥蛋白抗体及其用途
CA2461529A1 (en) * 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
US20060241067A1 (en) * 2002-06-25 2006-10-26 Varner Judith A Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
CN101094868B (zh) 2004-09-03 2013-07-10 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
IN266863B (hr) 2005-01-13 2015-06-10 Gene Techno Science Co Ltd
CA2653661A1 (en) 2006-05-31 2007-12-06 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
JP4841326B2 (ja) 2006-06-20 2011-12-21 三菱電機株式会社 ホームネットワークシステム
EP2316855B1 (en) * 2006-07-12 2016-09-21 Gene Techno Science Co., Ltd. Antihuman alpha-9 integrin antibody and use of the same
JP2008282496A (ja) 2007-05-11 2008-11-20 Konica Minolta Opto Inc 光ピックアップ装置
JP2007302676A (ja) * 2007-05-29 2007-11-22 Genentech Inc ヒト化抗β7アンタゴニストおよびその使用

Also Published As

Publication number Publication date
IL206898A (en) 2015-06-30
DK2243829T3 (da) 2014-11-17
JPWO2009088064A1 (ja) 2011-05-26
PT2243829E (pt) 2014-10-24
RU2010133550A (ru) 2012-02-20
WO2009088065A1 (ja) 2009-07-16
EP2243829A1 (en) 2010-10-27
EP2239323A1 (en) 2010-10-13
BRPI0905656A8 (pt) 2017-05-09
TWI432453B (zh) 2014-04-01
CN101918549B (zh) 2012-11-28
AU2009203369B2 (en) 2014-04-03
KR101634636B1 (ko) 2016-06-29
SI2243829T1 (sl) 2014-11-28
US20110014193A1 (en) 2011-01-20
CN101918549A (zh) 2010-12-15
JPWO2009088065A1 (ja) 2011-05-26
BRPI0905656A2 (pt) 2015-07-07
EP2239323A4 (en) 2012-05-23
AU2009203369A1 (en) 2009-07-16
BRPI0905656B1 (pt) 2020-03-31
CA2711882A1 (en) 2009-07-16
IL206898A0 (en) 2010-12-30
MX2010007515A (es) 2010-11-12
ZA201004770B (en) 2011-03-30
CA2711882C (en) 2016-07-19
EP2243829A4 (en) 2012-05-23
CY1115897T1 (el) 2017-01-25
TW200932759A (en) 2009-08-01
RU2503720C2 (ru) 2014-01-10
PL2243829T3 (pl) 2015-04-30
US20110059077A1 (en) 2011-03-10
US8603476B2 (en) 2013-12-10
KR20100110852A (ko) 2010-10-13
WO2009088064A1 (ja) 2009-07-16
ES2519047T3 (es) 2014-11-06
JP5440179B2 (ja) 2014-03-12
BRPI0905656B8 (pt) 2021-05-25
EP2243829B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
HRP20141110T1 (hr) Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo
HRP20140915T1 (hr) Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo
HRP20220081T1 (hr) Bcma i cd3 bispecifična t stanica koja uključuje konstrukte protutijela
HRP20201113T1 (hr) Vežući proteini protiv lag-3
HRP20210372T1 (hr) Anti-lag3 antitijela i antigen-vezujući fragmenti
HRP20190752T1 (hr) Novo protutijelo protiv ljudskog receptora tslp
HRP20191865T1 (hr) Novi heterodimerni proteini
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
HRP20211594T1 (hr) Anti-pd1 protutijela i načini uporabe
HRP20200189T1 (hr) Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije
HRP20191342T1 (hr) Anti-phf-tau antitijela i njihove upotrebe
HRP20161141T1 (hr) Anti-il-23 protutijela
HRP20150623T1 (hr) Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
HRP20180155T1 (hr) Novo protutijelo protiv ljudskog ngf
HRP20160131T1 (hr) Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba
HRP20220891T1 (hr) Protutijela, primjene i postupci
MY166282A (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
HRP20240774T1 (hr) Anti-il-33 antitijela i njihove upotrebe
HRP20211794T1 (hr) Humana antitijela za pd-1
MX353813B (es) Moleculas de union a vegf.
HRP20240676T1 (hr) Proteini domena skele na bazi fibronektina koji vezuju miostatin
JP2016532457A5 (hr)
RU2013140350A (ru) Антитела против человеческого il33r и их применение
HRP20211059T1 (hr) Antitijela za il-17c